IBS - Irritable Bowel Syndrome Clinical Trial
— PROBE2Official title:
L. Casei DG® (Lactobacillus Paracasei CNCMI1572) in the Treatment of Patients With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study.
Verified date | May 2022 |
Source | SOFAR S.p.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To assess the effect of L. casei DG® (Lactobacillus paracasei CNCMI1572; Enterolactis® plus) on abdominal symptoms and gut microbiota metabolism/composition in non constipated patients with IBS (Irritable Bowel Syndrome). Patients will be randomized to receive L. casei DG® capsules, b.i.d. for 12 weeks the a 4 weeks Follow Up period will follow.
Status | Completed |
Enrollment | 264 |
Est. completion date | December 30, 2021 |
Est. primary completion date | May 4, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age > 18 years and = 65 years - A positive diagnosis of non constipated IBS (i.e., IBS-D and IBS-M, both males and females), according to Rome IV criteria. - A negative outcome of colonoscopy performed within 5 years before screening if patient is at least 50 years old, or if patient meet any of the following alarm features: 1. Has a documented weight loss within the past 6 months; or 2. Has nocturnal symptoms; or 3. Has a familiar history of colon cancer; or 4. Has blood mixed with their stool (excluding blood from hemorroids). - Negative relevant additional screening or consultation whenever appropriate - Ability to conform to the study protocol. Exclusion Criteria: - Patients with IBS-C or IBS-U according to Rome IV criteria - Presence of any relevant organic, systemic or metabolic disease (particularly significant history of cardiac, renal, neurological, psychiatric, oncology, endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will be deemed clinically significant on the basis of predefined values, (i.e..liver or kidney functional levels 2-times greater than the upper reference values) - Ascertained intestinal organic diseases, including celiac disease, food allergies or inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diverticular disease, infectious colitis, ischemic colitis, microscopic colitis). - Previous major abdominal surgery. - Active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrolment are also acceptable). - Untreated food intolerance such as ascertained or suspected lactose intolerance, as defined by anamnestic evaluation or, if appropriate, lactose breath test. - Use of probiotics or topical and/or systemic antibiotic therapy during the last month. - Systematic/frequent use of contact laxatives. - Pregnant females or females of childbearing potential in the absence of effective contraceptive methods. - Inability to conform to protocol. - Treatment with any investigational drug within the previous 30 days. - Recent history or suspicion of alcohol abuse or drug addiction. - Presence of red or white flags at the Rome IV Psychosocial Alarm Questionnaire for Functional gastrointestinal Disorders. |
Country | Name | City | State |
---|---|---|---|
Italy | Gastroenterologia Universitaria Policlinico Giovanni XXIII | Bari | |
Italy | Azienda ULSS 1 | Belluno | |
Italy | Azienda Ospedaliero-Universitaria S. Orsola Malpighi | Bologna | |
Italy | A.O. "G. Brotzu"- Ospedale San Michele | Cagliari | CA |
Italy | AOU di Cagliari - Policlinico di Monserrato | Cagliari | CA |
Italy | Ospedale SS. Annunziata | Chieti | |
Italy | Ospedale Valduce | Como | CO |
Italy | ASST-FTB-Sacco | Milano | MI |
Italy | Fondazione IRCCS Policlinico | Milano | |
Italy | Policlinico | Napoli | |
Italy | Policlinico Federico II | Napoli | |
Italy | Azienda Ospedaliera di Padova | Padova | |
Italy | Fondazione IRCCS Policlinico S. Matteo | Pavia | |
Italy | U.O. Gastroenterologia Universitaria | Pisa | |
Italy | A.O. San Camillo-Forlanini | Roma | |
Italy | Ospedale Sant'Andrea | Roma | |
Italy | Policlinico Universitario Campus Biomedico | Roma | |
Italy | Policlinico San Donato | San Donato Milanese | MI |
Italy | A.O. Bolognini | Seriate | BG |
Italy | Ospedale Sant'Andrea | Vercelli | VC |
Lead Sponsor | Collaborator |
---|---|
SOFAR S.p.A. | 1Med |
Italy,
Barbara G, Feinle-Bisset C, Ghoshal UC, Quigley EM, Santos J, Vanner S, Vergnolle N, Zoetendal EG. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016 Feb 18. pii: S0016-5085(16)00219-5. doi: 10.1053/j.gastro.2016.02.028. [Epub ahead of print] — View Citation
Jalanka-Tuovinen J, Salojärvi J, Salonen A, Immonen O, Garsed K, Kelly FM, Zaitoun A, Palva A, Spiller RC, de Vos WM. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014 Nov;63(11):1737-45. doi: 10.1136/gutjnl-2013-305994. Epub 2013 Dec 5. — View Citation
Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009 Feb;104(2):404-10. doi: 10.1038/ajg.2008.86. Epub 2009 Jan 20. — View Citation
Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016 Feb 18. pii: S0016-5085(16)00222-5. doi: 10.1053/j.gastro.2016.02.031. [Epub ahead of print] — View Citation
Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010 Mar;59(3):325-32. doi: 10.1136/gut.2008.167270. Epub 2008 Dec 17. Review. — View Citation
Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J, Leffler DA, Marsh Z, Weitsman S, Chua KS, Barlow GM, Bortey E, Forbes W, Yu A, Chang C. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One. 2015 May 13;10(5):e0126438. doi: 10.1371/journal.pone.0126438. eCollection 2015. — View Citation
Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011 Nov;141(5):1792-801. doi: 10.1053/j.gastro.2011.07.043. Epub 2011 Aug 5. — View Citation
Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil. 2008 Oct;20(10):1110-8. doi: 10.1111/j.1365-2982.2008.01166.x. Epub 2008 Aug 6. — View Citation
Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167. Epub 2012 Jun 22. — View Citation
Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009 May;136(6):1979-88. doi: 10.1053/j.gastro.2009.02.074. Epub 2009 May 7. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients who have a response in pain | Patients who record on = 50% of the days a reduction of = 30% from their average baseline score for their worst abdominal pain.The standard 11-point numeric rating scale (from 0=none to 10=worst possible pain) will be used to measure abdominal pain. | 12 weeks | |
Primary | Proportion of patients who have a response in stool consistencies | Patients who record a stool-consistency score < 5 in the same days in which they record a reduction of = 30% from their average baseline score for their worst abdominal pain .For abnormal defecation, stool frequency and form will be measured using the Bristol Stool Form Scale (BSFS). | 12 weeks | |
Secondary | Evaluation of Pain relief | reduction of = 30% from baseline in the score for the worst abdominal pain on = 50% of days | 16 weeks | |
Secondary | Evaluation of global symptom score | Improvement in the global symptom score: a score of 0 or 1, or an improvement = 2 over the baseline score, on = 50% of days | 16 weeks | |
Secondary | Relief of IBS symptoms | Adequate relief of IBS symptoms on = 50% of the past weeks (a response of "yes" on =50% of the weeks to the following question: "Over the past week, have you had adequate relief of your IBS symptoms?)" | 16 weeks | |
Secondary | IBS-SSS score questionnaire (Severity Scoring System ) | To assess the severity of symptoms related to Irritable Bowel Syndrome, assessed at baseline and at the end of treatment after 12 weeks (it is considered clinically significant a score reduction of at least 50 points). The questionnaire is composed by five questions wich generate a maximum score of 100 each using prompted visual analogue scales, leading to a total possible score of 500. | 16 weeks | |
Secondary | Improvement in stool consistency | stool consistency score = 5 assessed with BSFS (Bristol Stool Form Scale) BSFS evaluates stool form and consistency (score from 1=dry stool to 7=liquid stoo. The ideal stool is generally 3 or 4) | 16 weeks | |
Secondary | Satisfaction with treatment | Overall satisfaction with treatment assessed by VAS scale (Visual Analogue Scale) | 16 weeks | |
Secondary | Quality of life | Quality of life assessment by validated Short-Form 12 Items Health Survey (SF-12) on a scale of 0 to 100 | 16 weeks | |
Secondary | Intake of rescue medication | type and frequencies of rescue medication | 16 weeks | |
Secondary | gut microbiota composition | Evaluation of changes in the gut microbiota composition and the relative abundance of bacterial OTUs (Operational Taxonomic Unit). | 16 weeks | |
Secondary | Short Chain Fatty Acids (SCFA) | Evaluation of Short Chain Fatty Acids levels in fecal samples | 16 weeks | |
Secondary | Free Aminoacids | Evaluation of Free aminoacids levels in fecal samples | 16 weeks | |
Secondary | Biogenic Amines | Evaluation of biogenic amines levels in fecal samples | 16 weeks | |
Secondary | Gut permeability for zonulin | evaluation of serum levels of zonulin | 16 weeks | |
Secondary | Gut permeability for citrulline | evaluation of serum levels of citrulline | 16 weeks | |
Secondary | Gut permeability for PV-1 (Plasmalemma vesicle-associated) protein | evaluation of serum levels of PV-1 (Plasmalemma vesicle-associated) protein | 16 weeks | |
Secondary | L. casei DG® strain in the feces | the recovery of L. casei DG® strain in the feces | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05118243 -
Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance
|
N/A | |
Completed |
NCT04422327 -
The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT05178017 -
Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
|
N/A | |
Completed |
NCT05197413 -
Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms
|
N/A | |
Completed |
NCT04905524 -
Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)
|
N/A | |
Recruiting |
NCT06297785 -
Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS)
|
N/A | |
Recruiting |
NCT05874830 -
The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome
|
N/A | |
Active, not recruiting |
NCT04723056 -
Zemedy Application for Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT05565612 -
Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT03131414 -
The IMAGINE-SPOR CIHR Chronic Disease Network
|
||
Completed |
NCT03333291 -
Fecal Transplantation in Patients With IBS
|
N/A | |
Recruiting |
NCT06215222 -
Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
|
||
Completed |
NCT05016596 -
Postprandial Lipids in IBS and Nutritional Treatment
|
N/A | |
Recruiting |
NCT04760353 -
The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT06426745 -
Split-dose Versus Single-dose Bowel Preparation for Colonoscopy
|
N/A | |
Recruiting |
NCT04217733 -
Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
|
Phase 3 | |
Completed |
NCT03178877 -
The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors
|
N/A | |
Recruiting |
NCT05990764 -
Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)
|
N/A | |
Completed |
NCT03948854 -
Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients
|
N/A | |
Completed |
NCT04898257 -
Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients
|
N/A |